Pluri (NASDAQ:PLUR) Shares to Reverse Split on Monday, April 1st

Pluri Inc. (NASDAQ:PLUR)’s stock is set to reverse split before the market opens on Monday, April 1st. The 1-8 reverse split was announced on Monday, April 1st. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 1st.

Pluri Stock Down 13.7 %

Pluri stock opened at $0.88 on Thursday. The company has a debt-to-equity ratio of 3.69, a current ratio of 7.12 and a quick ratio of 7.12. The business has a 50 day simple moving average of $0.81 and a 200-day simple moving average of $0.65. The stock has a market capitalization of $36.49 million, a PE ratio of -1.52 and a beta of 1.45. Pluri has a 12 month low of $0.43 and a 12 month high of $1.07.

Pluri (NASDAQ:PLUR) last issued its quarterly earnings results on Monday, February 12th. The company reported ($0.12) earnings per share (EPS) for the quarter. The firm had revenue of $0.11 million during the quarter. Pluri had a negative return on equity of 177.94% and a negative net margin of 6,708.40%.

Institutional Trading of Pluri

A number of institutional investors have recently made changes to their positions in PLUR. Renaissance Technologies LLC acquired a new stake in shares of Pluri in the third quarter worth approximately $81,000. Values First Advisors Inc. boosted its stake in Pluri by 168.4% during the third quarter. Values First Advisors Inc. now owns 135,547 shares of the company’s stock worth $81,000 after buying an additional 85,037 shares during the last quarter. Jane Street Group LLC boosted its stake in Pluri by 166.5% during the fourth quarter. Jane Street Group LLC now owns 95,906 shares of the company’s stock worth $90,000 after buying an additional 59,920 shares during the last quarter. Finally, Citadel Advisors LLC boosted its stake in Pluri by 128.1% during the fourth quarter. Citadel Advisors LLC now owns 57,481 shares of the company’s stock worth $33,000 after buying an additional 32,279 shares during the last quarter. 16.59% of the stock is owned by institutional investors and hedge funds.

About Pluri

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.